Novo Nordisk Pharmaceuticals, Inc.
2021 Estimated Media Spend: $******
2019 Revenue: $122,021,000,000.00
As the U.S. affiliate of Novo Nordisk A/S in Copenhagen, Denmark, Novo Nordisk Pharmaceuticals develops and manufactures biopharmaceuticals and diabetes care products. Novo Nordisk was the first company to create the insulin pen and today is a leader in human and analog insulin distribution. Novo Nordisk is also dedicated to creating pharmaceuticals for those with hemophilia and hormone deficiencies. North American headquarters are located in Princeton, NJ.** NOTE: As a privately held subsidiary of a publicly traded parent company, annual revenue and employee count are not readily available. Therefore, the revenue and employee figures presented below are those of the parent company. **